<DOC>
	<DOCNO>NCT02656095</DOCNO>
	<brief_summary>This study plan learn measure Lipoprotein lipase ( LPL ) activity human . LPL enzyme breakdown certain type fat small part . Lipoprotein lipase deficiency ( LPLD ) rare genetic disorder lipoprotein enzyme longer functional . This cause condition know high triglyceride blood inflammation pancreas . Investigational medication treat LPLD currently develop . In order see medication effective , necessary able accurately measure LPL activity human . LPL activity successfully measure animal model give heparin . Heparin blood thinner approve FDA . It originally use prevent blood clot . This study administer heparin healthy adult intravenous infusion ( IV ) . Blood sample collect infusion test LDL level . The purpose study develop cheap , reliable standard assessment LPLD patient</brief_summary>
	<brief_title>Lipoprotein Lipase Enzyme Activity Assay Validation Clinical Assessment</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipoproteinemia Type I</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1. male female age 2039 1 . Past history LPL deficiency 2 . Hypercholesterolemia ( Cholesterol &gt; 200 , LDL &gt; 160 , HDL &lt; 35 ) hypertriglyceridemia ( TG &gt; 150 ) , familial lipid disorder 3 . Diabetes mellitus ( type 1 2 ) 4 . Uncontrolled hypertension SBP &gt; 140 , DBP &gt; 90 5 . History hemorrhagic stroke 6 . Current pregnancy 7 . History major surgery , invasive procedure trauma within last 30 day , plan major surgery within 30 day participate study 8 . Exposure heparin ( unfractionated heparin low molecular weight heparin ) within 30 day prior screen 9 . History allergy heparin 10 . History heparininduced thrombocytopenia 11 . Current smoking 12 . Active ulcerative angiodysplastic GI diseases 13 . Thrombocytopenia platelet disorder ( Platelet count &lt; 100,000/UL ) 14 . Major health issue may affect safety study subject , include limited : History chronic kidney disease ( eGFR &lt; 60 ) Long term use medication alter lipid metabolism History hepatic disease ( ALT AST 2 time upper limit normal ) History clot disorder , type coagulation factor deficiency , thrombocytopenia Chronic use ASA , anticoagulant , platelet inhibitor Use NSAIDS 2 week prior screen Anemia ( hemoglobin &lt; 13 g/dL )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>